Daniels-Feasel v. Forest Pharmaceuticals, Inc.
- Laura Swain
- 1:17-cv-04188
- U.S. District Court · Southern District of New York
- 5
Daniels-Feasel v. Forest Pharmaceuticals: Chief Judge Swain granted summary judgment because plaintiffs lacked expert evidence needed to prove Lexapro caused the children’s disorders.
The ruling ended the claims of the mothers and children who alleged that prenatal Lexapro exposure caused the children’s neurodevelopmental disorders, including autism spectrum disorder, and entered judgment for Forest Laboratories Inc., Forest Laboratories, LLC, Forest Pharmaceuticals, Inc., and Allergan PLC.
What happened
In Daniels-Feasel v. Forest Pharmaceuticals, several mothers and their children claimed that taking Lexapro during pregnancy caused the children to develop neurodevelopmental disorders, including autism spectrum disorder.
The court had previously excluded all three of the plaintiffs’ proposed experts on general causation because their testimony was unreliable. Without those experts, the plaintiffs could not present evidence that Lexapro can cause the alleged disorders.
Chief Judge Laura Taylor Swain granted the defendants’ motion for summary judgment, directed the Clerk to enter judgment for the defendants, and ordered the case closed.
The detailed version
- Daniels-Feasel v. Forest Pharmaceuticals, Inc. · No. 1:17-cv-04188
- Laura Swain
- Dec. 29, 2021
Background
This medical-products liability case concerns Lexapro, a prescription antidepressant sold and manufactured by the defendants Forest Laboratories Inc., Forest Laboratories, LLC, Forest Pharmaceuticals, Inc., and Allergan PLC. The plaintiffs—several mothers and their children—alleged that the mothers’ use of Lexapro during pregnancy caused the children to develop neurodevelopmental disorders, including autism spectrum disorder. The defendants removed the case from New York state court to the Southern District of New York based on diversity jurisdiction.
Earlier Expert-Evidence Ruling
The defendants moved to exclude the testimony of the plaintiffs’ three proposed experts on general causation under Federal Rule of Evidence 702 and the standard established in Daubert v. Merrell Dow Pharmaceuticals, Inc. General causation means evidence that exposure to a substance can cause a particular disease. On September 3, 2021, the court granted that motion in its entirety and excluded all three experts’ testimony as unreliable.
Summary Judgment Analysis
The defendants then moved for summary judgment. Summary judgment is a ruling entered when there is no genuine dispute about a material fact and the moving party is entitled to judgment under the law. The court explained that causation is required in products-liability cases and has both general and specific components. In complex medical-products cases, expert testimony is generally required to establish general causation.
Because the court had excluded all of the plaintiffs’ proposed causation experts, the plaintiffs had no expert testimony with which to prove general causation. The plaintiffs conceded that the earlier order prevented them from making a good-faith opposition to summary judgment and made summary judgment inevitable. The court therefore concluded that the plaintiffs could not establish an essential element of their claims and that no triable issue of material fact remained.
Disposition
Judge Laura Taylor Swain granted the defendants’ motion for summary judgment dismissing the plaintiffs’ complaint. The court directed the Clerk of Court to enter judgment in the defendants’ favor and close the case.
Read the full 5-page opinion on CourtListener, the free public archive maintained by the Free Law Project.